Olea Venture Partners is an early-stage venture capital fund focused on healthcare and life sciences. We invest in companies addressing some of the most urgent needs in health and longevity, with the ambition to build enduring, internationally competitive businesses.
We are backed by the European Investment Fund (EIF) alongside leading institutional investors who provide strong strategic validation of our platform.
The founding partners bring over 50 years of combined global experience across the US, UK, and Europe, spanning capital allocation, venture building, and leadership in top-tier healthcare and life sciences organisations. We take a hands-on value-creation approach, combining co-building with practical strategic and operational support, informed by our experience scaling businesses across global markets.
Our edge lies in how we engage: attention to detail, high standards of execution, and thoughtful, long-term commitment. We work closely with founders to help turn ambitious ideas into exceptional, trusted products and create durable impact within healthcare systems.
We believe exceptional companies are built through a combination of strong vision and disciplined execution. The difference is often found in small details and decisions:
how products are designed, how evidence is generated, how teams operate day to day.
We share this mindset and partner best with founders who do the same: teams who care deeply about what they build and understand that details shape outcomes and outcomes shape lives, especially in healthcare and biotechnology.
Healthcare and life sciences are inherently complex. Clinical timelines shift, regulatory paths evolve, patient adoption determines success, and teams must adapt continuously.
Having built and led businesses in these environments, we help founders navigate this with structure and judgment. This often means:
We help teams build the muscle to adapt and endure.
Our global network spans clinicians, researchers, hospitals, payors, regulators, pharmaceutical and med-tech leaders, and international investors.
We engage this network thoughtfully and purposefully with clear context, specific objectives, and an emphasis on outcomes.
We work closely with founders from the earliest stages, supporting the areas where our experience truly adds value – strategy, execution, science, regulation, and commercialization.
Our approach is defined by clarity and care:
